金昌人去医院体检一下多少钱啊平凉查心脏多少钱,黄山脏b超主要检查什么,蚌埠年人体检要体检什么项目,广安痛会是什么原因,新余身体健康检查多少钱,阿拉善盟肠胃检查一般要花多少钱,随州康检查去哪里好呀

New York, Sept. 23 (Xinhua) -- A Chinese scientist was presented a prestigious U.S. award on Friday for the discovery of artemisinin, a drug therapy for malaria that has saved millions of lives across the globe, especially in the developing world.Pharmacologist Tu Youyou, 81, became the first scientist on the Chinese mainland to win Lasker Award, known as "America's Nobels" for their knack of gaining future recognition by the Nobel committee.Tu, a scientist at the China Academy of Chinese Medical Sciences in Beijing, pioneered a new approach to malaria treatment that has benefited hundreds of millions of people and promises to benefit many times more. By applying modern techniques and rigor to a heritage provided by 5000 years of Chinese traditional practitioners, she has delivered its riches into the 21st century."Not often in the history of clinical medicine can we celebrate a discovery that has eased the pain and distress of hundreds of millions of people and saved the lives of countless numbers of people, particularly children, in over 100 countries," Lucy Shapiro, a member of the award jury and professor of Stanford University, said while describing Tu' s discovery.Shapiro said the discovery, chemical identification, and validation of artemisinin, a highly effective anti-malarial drug, is largely due to the "scientific insight, vision and dogged determination" of Professor Tu and her team. She thought Professor Tu's work has provided the world with arguably the most important pharmaceutical intervention in the last half century."The discovery of artemisinin is a gift to mankind from traditional Chinese medicine," Tu said while receiving the award. "Continuous exploration and development of traditional medicine will, without doubt, bring more medicines to the world."

WASHINGTON, June 21 (Xinhua) -- A new study from Harvard School of Public Health (HSPH) and University of California, San Francisco, researchers suggests that men with prostate cancer who smoke increase their risk of prostate cancer recurrence and of dying from the disease. The study will be published Wednesday in the Journal of the American Medical Association."In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said Stacey Kenfield, lead author and a research associate in the HSPH Department of Epidemiology. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."Kenfield and her colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32 percent) due to prostate cancer, 416 (26 percent) due to cardiovascular disease, and 878 prostate cancer recurrences.The researchers found that men with prostate cancer who were current smokers had a 61 percent increased risk of dying from prostate cancer, and a 61 percent higher risk of recurrence compared with men who never smoked. Smoking was associated with a more aggressive disease at diagnosis, defined as a higher clinical stage or Gleason grade (a measure of prostate cancer severity). However, among men with non-metastatic disease at diagnosis, current smokers had an 80 percent increased risk of dying from prostate cancer.Compared with current smokers, men with prostate cancer who had quit smoking for 10 or more years, or who had quit for less than 10 years but smoked less than 20 pack-years before diagnosis, had prostate cancer mortality risk similar to men who had never smoked. Men who had quit smoking for less than 10 years and had smoked 20 or more pack-years had risks similar to current smokers."These data are exciting because there are few known ways for a man to reduce his risk of dying from prostate cancer," said senior author Edward Giovannucci, professor of nutrition and epidemiology at HSPH. "For smokers, quitting can impact their risk of dying from prostate cancer. This is another reason to not smoke."Prostate cancer is the most frequently diagnosed form of cancer diagnosed in the United States and the second leading cause of cancer death among U.S. men, affecting one in six men during their lifetime. More than two million men in the U.S. and 16 million men worldwide are prostate cancer survivors.

WASHINGTON, July 20 (Xinhua) -- The loss of a protein that coats sperm may explain a significant proportion of infertility in men worldwide, according to a study by an international team of researchers led by University of California Davis.A paper describing the work was published Wednesday in the journal Science Translational Medicine. The research could open up new ways to screen and treat couples for infertility.The gene DEFB126 encodes a protein called Beta Defensin 126, which coats the surface of sperm and helps it penetrate cervical mucus in the female. A survey of samples from the U.S., Britain and China showed that as many as a quarter of men worldwide carry two copies of the defective gene.In the new study, researchers found that men with a muted DEFB126 lack Beta Defensin 126, making it much more difficult for sperm to swim through the mucus and eventually join with an egg.Examining 500 newly married Chinese couples, researchers found that the lack of Beta Defensin 126 in men with the DEFB126 mutation lowered fertility (even among men that did not display other deficiencies usually associated with infertility, like inadequate semen volume and low sperm motility). Wives of men with the Beta Defensin 126 variant were significantly less likely to become pregnant than were other couples, and 30 percent less likely to have a birth.This genetic variation in DEFB126 likely accounts for many unexplained cases of infertility, researchers say. They hope next to work with a major infertility program in the U.S. to further explore the role of the mutation.

LOS ANGELES, June 8 (Xinhua) -- NASA's Mars Exploration Rover Opportunity is heading toward "Spirit Point" on the rim of a large crater, a long-term destination that the rover has been trying to reach for nearly three years, the Jet Propulsion Laboratory (JPL) announced on Wednesday.Opportunity has moved toward the crater, Endeavour, since climbing out of Victoria crater in August 2008.Having driven 11 miles (18 kilometers), the rover has about two miles (about three kilometers) to go before reaching the rim of Endeavour, said JPL in Pasadena, Los Angeles.Rover team members last week selected "Spirit Point" as the informal name for the site on the rim where Opportunity will arrive at Endeavour crater. The choice commemorates Opportunity's rover twin, Spirit, which has ended communication and finished its mission."Spirit achieved far more than we ever could have hoped when we designed her," said Steve Squyres of Cornell University, Ithaca, New York, principal investigator for the rovers. "This name will be a reminder that we need to keep pushing as hard as we can to make new discoveries with Opportunity. The exploration of Spirit Point is the next major goal for us to strive for."Endeavour offers the setting for plenty of productive work by Opportunity. The crater is 14 miles (22 kilometers) in diameter -- more than 20 times wider than Victoria crater, which Opportunity examined for two years. Orbital observations indicate that the ridges along its western rim expose rock outcrops older than any Opportunity has seen so far. Spirit Point is at the southern tip of one of those ridges, "Cape York," on the western side of Endeavour.Opportunity and Spirit completed their three-month prime missions on Mars in April 2004. Both rovers continued for years of bonus, extended missions. Both have made important discoveries about wet environments on ancient Mars that may have been favorable for supporting microbial life.NASA's JPL, a division of the California Institute of Technology in Pasadena, manages the Mars Exploration Rover Project for the NASA Science Mission Directorate, Washington.

SYDNEY, Aug. 25 (Xinhua) -- Scientists in Australia have discovered a way of stopping mosquitoes carrying dengue virus, raising hopes for preventing the 50 million human cases of the disease every year, local media reported on Thursday.Groundbreaking experiments in Queensland have found a common insect bacteria, wMel Wolbachia, which can dramatically reduce the presence of dengue fever in mosquitoes.The research, led by Professor Scott O'Neill, Dean at Melbourne's Monash University, was published on Thursday in the prestigious journal, Nature.Australian researchers working on the Eliminate Dengue program aim to protect the mosquitoes themselves from dengue and so stop them transmitting the virus to humans."What the experiments have shown is that this strain of Wolbachia when it is put into mosquitoes really reduces the ability of the (dengue) virus to grow in the mosquito and if it can't grow, then it can't get transmitted in people," O'Neill told reporters.O'Neill said while it was too early to say if the experiments heralded the end of dengue fever, it was a major step towards that goal.In the past decade, there have been 2400 cases of dengue fever reported during 36 outbreaks in Australia.Dengue fever has become endemic in tropical regions, where it is spread by a specific type of mosquito that becomes infected after biting humans with the disease.Despite millions of people being infected with dengue each year, there is currently no way of stopping its rapid spread either by vaccines or controlling mosquito populations.Further trials will be conducted in Cairns in north Queensland over the coming wet season and approval is currently being sought for trials in Thailand, Vietnam, Brazil and Indonesia that will directly determine the effectiveness of the method in reducing dengue disease in human populations, according to Monash University.